Literature DB >> 24887033

The use of optical imaging to assess the potential for embryo-fetal exposure to an exogenous material after intravaginal administration.

James Cao1, Xiaoyou Ying1, Bruce K Beyer2, Anthony M DeLise3.   

Abstract

A β-actin-luc transgenic mouse model was used to evaluate whether embryo-fetal exposure could occur after intravaginal administration of a compound. A bioluminescent substrate, d-luciferin, was delivered intravaginally to mimic compound exposure to the female reproductive track and the embryo-fetus. Bioluminescence was observed throughout the reproductive tract during diestrus, but not during estrus, 2-5min after intravaginal d-luciferin administration to female β-actin-luc mice. Intravaginal administration of d-luciferin to wild-type females mated with male β-actin-luc mice indicated that the substrate reached the developing embryo-fetus, with bioluminescence corresponding to transgene expression in the embryo-fetus. d-Luciferin substrate rapidly reached the embryo-fetus regardless of the administration route (intravaginal, intraperitoneal, subcutaneous, or intravenous). Vaginal ligation appeared to block at least some direct exposure to the embryo-fetus, but did not prevent d-luciferin from eventually reaching the embryo-fetus. Additional work will be necessary to form the basis for a reliable assessment of the human risk for male-mediated teratogenicity.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bioluminescence; Embryo; Fetus; Fluorescence; Imaging; Intravaginal; Risk assessment; d-Luciferin

Mesh:

Substances:

Year:  2014        PMID: 24887033     DOI: 10.1016/j.reprotox.2014.05.010

Source DB:  PubMed          Journal:  Reprod Toxicol        ISSN: 0890-6238            Impact factor:   3.143


  2 in total

1.  Bioluminescent imaging of ABCG2 efflux activity at the blood-placenta barrier.

Authors:  Jeyan S Kumar; Bih-Rong Wei; James P Madigan; R Mark Simpson; Matthew D Hall; Michael M Gottesman
Journal:  Sci Rep       Date:  2016-02-08       Impact factor: 4.379

2.  Birth Control in Clinical Trials: Industry Survey of Current Use Practices, Governance, and Monitoring.

Authors:  J Stewart; W J Breslin; B K Beyer; K Chadwick; L De Schaepdrijver; M Desai; B Enright; W Foster; J Y Hui; G J Moffat; B Tornesi; K Van Malderen; L Wiesner; C L Chen
Journal:  Ther Innov Regul Sci       Date:  2015-10-08       Impact factor: 1.778

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.